SironRX Raises $3.4M for SDF-1 Wound Therapy Trials

SironRX Therapeutics Inc., a regenerative medicine spinoff from the Cleveland Clinic that is developing a topical therapy to accelerate dermal and bone healing and decrease scar formation, closed a $3.4 million Series A investment. The company plans to use the funds to begin clinical trials of its wound therapy technology and to build its senior management and clinical team, according to Rahul Aras, the company's co-founder, president and CEO.